<DOC>
	<DOCNO>NCT01257477</DOCNO>
	<brief_summary>An observational study evaluate LOTRONEX® woman severe IBS-D current clinical practice setting .</brief_summary>
	<brief_title>LOTRONEX® Severe Diarrhea-Predominant Irritable Bowel Syndrome ( IBS-D )</brief_title>
	<detailed_description>This observational study evaluate effect Lotronex® use current clinical practice set symptom relief , specifically , improvement bowel habit IBS pain . Patients plan initiate commercially available LOTRONEX® therapy consent study participation . Patients complete study questionnaire relate bowel symptom , prior therapy , quality life , productivity loss treatment outcome . Investigators also ask complete questionnaire relate patient 's disease characteristic , patient progress study medication treatment outcome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Alosetron</mesh_term>
	<criteria>1 . Be female 18 65 year age ( inclusive ) Visit 1 . 2 . Sign date write informed consent form prior initiation studyrelated activity , include discontinuation prohibit medication . 3 . Be diagnose severe , diarrheapredominant IBS . 4 . Have experience chronic IBS symptom last 6 month longer . 5 . Have respond adequately IBS therapy . 6 . Be able read , understand sign inform consent , applicable , Authorization Use Disclose Protected Health Information form ( consistent Health Insurance Portability Accountability Act 1996 [ HIPAA ] legislation ) , answer study questionnaire , communicate investigator , understand comply protocol requirement . 1 . Has period 3 consecutive day without bowel movement past 14 day . 2 . In past 14 day , evidence chronic severe constipation , history chronic severe constipation , history sequelae constipation . 3 . Has recurrent bowel obstruction small intestine colon . 4 . Has bloody diarrhea abdominal pain rectal bleeding past 14 day ( except rectal bleeding due hemorrhoid ) . 5 . Has know biochemical anatomical abnormality gastrointestinal tract . 6 . Has history thrombophlebitis hypercoagulable state . 7 . Has history atherosclerosis . 8 . Has medical surgical condition judgment investigator make patient inappropriate candidate Lotronex® therapy ( e.g. , unstable cardiovascular , autoimmune , renal , hepatic , pulmonary , endocrine , metabolic , gastrointestinal , hematologic , neurological condition ; recent ongoing malignancy ; evidence hepatic dysfunction ; renal impairment . ) 9 . Mental impairment inability understand medication guide instruction study participation refusal comply protocol . 10 . Current ( within 7 day start Lotronex® use ) use fluvoxamine . 11 . Chronic ( ≥ 6 month ) use narcotics opioids . 12 . The patient use investigational drug participate investigational study within 30 day Visit 1/ Screening Visit . 13 . The patient hypersensitive know negative response 5HT3 antagonist . 14 . Had significant adverse event previous treatment Lotronex® currently use Lotronex® .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Diarrhea</keyword>
	<keyword>IBS</keyword>
	<keyword>Irritable Bowel Syndrome</keyword>
</DOC>